Supported Features
-
Larger Text
-
Dark Interface
-
Sufficient Contrast
Resilience-h2020
Medical
Free · Designed for iPad. Not verified for macOS.
RESILIENCE Proyect
A European Commission-funded project aimed at reducing the incidence of heart failure in cancer survivors
Cancer survivors are at high risk for cardiovascular complications. Anthracyclines are an extremely effective treatment against many cancer types, but they can induce cardiac toxicity resulting in chronic heart failure.
RESILIENCE Project tests a novel preventive intervention (remote ischemic conditioning) in patients at risk for anthracycline-induced cardiotoxicity. In addition, new diagnostic modalities will be used to identify anthracyclines-induced cardiotoxicity in its very early stages.
RESILIENCE counts on a multidisciplinary consortium with the active participation of patients.
Ratings & Reviews
- This app hasn’t received enough ratings or reviews to display an overview.
Bug fixes, usability and design improvements.
The developer, Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.), indicated that the app’s privacy practices may include handling of data as described below. For more information, see the developer’s privacy policy .
Data Not Collected
The developer does not collect any data from this app.
The developer indicated that this app supports the following accessibility features. Learn More
Information
- Seller
- Centro Nacional de Investigaciones Cardiovasculares Carlos III F.S.P.
- Size
- 34.4 MB
- Category
- Medical
- Compatibility
Requires iOS 15.6 or later.
- iPhone
Requires iOS 15.6 or later. - iPad
Requires iPadOS 15.6 or later. - iPod touch
Requires iOS 15.6 or later. - Mac
Requires macOS 12.5 or later and a Mac with Apple M1 chip or later. - Apple Vision
Requires visionOS 1.0 or later.
- iPhone
- Languages
English and 5 more
- English, Danish, French, German, Portuguese, Spanish
- Age Rating
13+
- 13+
- Infrequent
Medical Treatment information
Contains
Messaging and Chat
Health or Wellness Topics
- Copyright
- © 2020-2021 Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.)